生产企业：Jiangsu Vcare PharmaTech Co., Ltd.
VC-005 is a new-generation highly selective JAK1 inhibitor being developed by Jiangsu Vcare PharmaTech Co., Ltd. It is being developed via both oral and topical formulations for full-population treatment of atopic dermatitis, with all indications in Phase III clinical trials. The asset is also under clinical development for ankylosing spondylitis, vitiligo, alopecia areata and other autoimmune diseases.
VC-005 is a new-generation highly selective JAK1 inhibitor being developed by Jiangsu Vcare PharmaTech Co., Ltd. It is being developed via both oral and topical formulations for full-population treatment of atopic dermatitis, with all indications in Phase III clinical trials. The asset is also under clinical development for ankylosing spondylitis, vitiligo, alopecia areata and other autoimmune diseases.
Highly selective JAK1 inhibitor
Atopic dermatitis (Phase III clinical trials); also under clinical development for ankylosing spondylitis, vitiligo, and alopecia areata.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
